From the browser to the back end, the ‘boring’ choice is exciting again. We look at three trends converging to bring SQL back ...
Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results